<DOC>
	<DOCNO>NCT02438644</DOCNO>
	<brief_summary>This observational , noninterventional study design characterize effectiveness safety profile vismodegib ( Erivedge ) Argentine patient . Only patient locally advance basal cell carcinoma ( laBCC ) metastatic basal cell carcinoma ( mBCC ) consider effectiveness analysis . Study duration estimate approximately 12 month .</brief_summary>
	<brief_title>Observational Study Vismodegib ( Erivedge ) Patients Treated Argentina</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<criteria>Argetine patient prescribe vismodegib accord standard care line Summary Product Characteristics ( SPC ) local label Diagnosis laBCC mBCC effectiveness analysis None specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>